RxDoctor Payments Data

Luke Peterson, MD

Ophthalmology · Matthews, NCNPI 1659698967

Payments from drug & device makers

$13,323in general payments, 2019–2025

Across 320 payments — averaging $41.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NEW World Medical,inc.$5K
  • Alcon$3K
  • AbbVie$2K
  • Novartis$612
  • Sun Pharmaceutical Industries Inc.$505
  • Rxsight Inc$423
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$1,50011%
  • Speaking & faculty fees$2,50019%
  • Food & beverage$9,14369%
  • Gifts$1801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,323 in reported general payments places this provider in the 85th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$484,755
Medicare patients
968
Services billed
5,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod220$111,172
RestasisCyclosporine86$107,862
XiidraLifitegrast62$91,929
LumiganBimatoprost152$84,078
RocklatanNetarsudil Mesylat/Latanoprost59$32,745
SimbrinzaBrinzolamide/Brimonidine Tart115$27,613
CombiganBrimonidine Tartrate/Timolol64$26,212
Prednisolone Acetate650$25,849
Latanoprost1,866$22,374
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol110$18,975
Travoprost101$18,021
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,030$17,344
Cyclosporine33$14,668
Brimonidine Tartrate538$11,850
RhopressaNetarsudil Mesylate26$11,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$1,898$229,896334 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$233$203,102282 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$184$44,57785 claims
AlconSimbrinza$2,718$27,613115 claims
Sun Pharmaceutical Industries Inc.Cequa$505$10,65615 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$126$3,46136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Matthews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →